Clinical trials: Liver Malignant Tumors
Biliary Tract Neoplasms, Liver Cancer
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
BACKGROUND: Various tumor ablative procedures and techniques have been shown to result in immunogenic cell death and induction of a peripheral immune response.
- Conditions
- Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma
- Trial name
- NCT02821754
- Testing
- Durvalumab, Tremelimumab, Trans-arterial Catheter Chemoembolization (TACE)
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer, Small Bowel Cancer
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
The objective of this expanded access program is to provide ulixertinib (BVD-523) for compassionate use in advanced cancer patients with MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF…
- Conditions
- Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer, Melanoma
- Trial name
- NCT04566393
- Testing
- Ulixertinib (BVD-523)
- Where
- 26 sites in United States
- Sponsor
- xCures
Metastatic Colon Cancer, Liver Cancer
Hepatic Artery Infusion (HAI) Program at Duke University
The Duke HAI program was implemented in November 2018 and treated 30 patients in its first 17 months using the Medtronic Synchromed II device (only commercially available device suitable for HAI for cancer patients).
- Conditions
- Metastatic Colon Cancer, Liver Cancer, Intrahepatic Cholangiocarcinoma
- Trial name
- NCT04511793
- Testing
- Medtronic Synchromed II pump
- Sponsor
- Michael Lidsky, M.D.
Hepatocellular Carcinoma, Very-early Stage
Standard Treatments of Very-early Stage Hepatocellular Carcinoma
The aim of our study was to elucidate the difference in the rates of complication, hospitalization days, medical expenses, MRI showed that the degree of tumor necrosis, and overall survival rates of the therapies between PEI, MVA…
- Trial name
- NCT02728193
- Testing
- RFA, MWV, PEI
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma
JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer
This is a multicenter, randomized, open-label, controlled Phase III clinical study designed to evaluate the efficacy and safety of JS207 in combination with JS007 versus toripalimab in combination with bevacizumab as first-line…
- Trial name
- NCT07823348
- Testing
- JS207, JS007, Toripalimab
- Where
- 2 sites in China
- Volunteers
- 560 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Hepatocellular Carcinoma
GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of infused autologous armored GPC3-directed CAR-T in patients with advanced hepatocellular carcinoma refractory to prior…
- Trial name
- NCT05926726
- Testing
- CAR-GPC3 T cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- RenJi Hospital
Hepatocellular Carcinoma
Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with placebo on overall survival in subjects with advanced hepatocellular carcinoma who have received prior sorafenib.
- Trial name
- CELESTIAL (NCT01908426)
- Testing
- Cabozantinib tablets
- Where
- 104 sites in United States, Australia and 17 more
- Volunteers
- 707 people
- Sponsor
- Exelixis
Hepatocellular Carcinoma
Impact of Preoperative Serum Albumin Level on Postoperative Outcomes in Chinese HCC Patients Treated With Surgery
This is an observational and retrospective cohort study to evaluate the impact of the preoperative serum albumin concentration on postoperative outcomes among hepatocellular carcinoma (HCC) patients who received hepatectomy or…
- Trial name
- REAL (NCT05970159)
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma (HCC)
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
A Trial to Evaluate the Efficacy and Safety of Camrelizumab Plus Rivoceranib (Apatinib) Versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative…
- Trial name
- NCT04639180
- Testing
- Camrelizumab, Rivoceranib (Apatinib)
- Where
- 6 sites in China
- Volunteers
- 687 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma
Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）.
This study is a single-center, open-label Phase II clinical trial, aiming to enroll approximately 30 unresectable BCLC stage B or C hepatocellular carcinoma (HCC) patients from China.
- Trial name
- NCT06375486
- Testing
- Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
CT Scans Prior to Surgery With a Least 2 Years of Follow-up
Identification of Image Phenotypes to Predict Recurrence After Resection of Hepatocellular Carcinoma
Tumor recurrence, which occurs in 70% of patients with HCC within 5 years after hepatic resection, is a major cause of post-resection-death.
- Trial name
- LIVERIBIOPSY (NCT05235490)
- Testing
- Non intervention
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatocellular Carcinoma
AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma
A study that aimed to assess the safety and anti-tumor activity of C-TCR055 injection in unresectable HCC patients
- Trial name
- NCT04368182
- Testing
- Autologous C-TCR055
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Zhejiang University
Carcinoma, Hepatocellular
A Phase I Study of Pazopanib in Adult Patients With Liver Cancer
Liver cancer is a good target for anti-angiogenic treatments such as pazopanib. The effect of pazopanib in patients with liver cancer are unknown.
- Trial name
- NCT00370513
- Testing
- pazopanib
- Where
- 3 sites in United States, Hong Kong and 1 more
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (Icc)
Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, BTC or NEN
Precision medicine represents a major goal in oncology. It has its underpinning in the identification of biomarkers with diagnostic, prognostic, or predictive values.
- Conditions
- Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (Icc), Neuroendocrine Tumors
- Trial name
- ELEGANCE (NCT06735560)
- Testing
- 89Zr-TLX250 PET/CT
- Where
- 2 sites in France
- Volunteers
- 60 people
- Sponsor
- Nantes University Hospital
Liver Transplantation, Hepatocellular Carcinoma
Impact of Postoperative Adjuvant Chemotherapy in Patients With Hepatocellular Carcinoma After Liver Transplantation
The study is designed to investigate the effect of postoperative adjuvant chemotherapy in prevention of tumor recurrence and metastasis for hepatocellular carcinoma after liver transplantation.
- Conditions
- Liver Transplantation, Hepatocellular Carcinoma, Tumor Recurrence and Metastasis, Survival
- Trial name
- NCT01125020
- Testing
- gemcitabine and oxaliplatin, doxorubicin, 5-Fu and cisplatin
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Carcinoma, Hepatocellular
A Study of LY2157299 in Participants With Hepatocellular Carcinoma
The purpose of this study is to estimate the median time to progression in participants with hepatocellular carcinoma (HCC) when treated with LY2157299 as monotherapy and in combination with sorafenib or ramucirumab.
- Trial name
- NCT01246986
- Testing
- LY2157299, Sorafenib, Ramucirumab
- Where
- 40 sites in United States, Australia and 5 more
- Volunteers
- 204 people
- Sponsor
- Eli Lilly and Company
Hepatocellular Carcinoma
Bevacizumab in Advanced Hepatocellular Carcinoma
Primary liver cancer (hepatocellular carcinoma) is the fifth most common malignant disorder, with an increasing incidence in Europe and the USA as a result of the high prevalence of hepatitis C.
- Trial name
- NCT00162669
- Testing
- bevacizumab
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Hepatocellular Carcinoma, Neoplasm Metastasis
Capecitabine to Prevent Recurrence of Hepatocellular Carcinoma After Curative Resection
The purpose of this study is to determine whether capecitabine is effective to prevent disease recurrence after curative hepatic resection in patients with hepatocellular carcinoma.
- Trial name
- NCT00561522
- Testing
- Capecitabine, No other preventive treatment
- Where
- China
- Volunteers
- 290 people
- Sponsor
- Fudan University
Gastric Cancer, Hepatic Carcinoma
Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia
This study retrospectively analyzed patients who underwent tracheal intubation under general anesthesia at the First Affiliated Hospital of Zhejiang University School of Medicine between October 1, 2015, and September 30, 2025…
- Conditions
- Gastric Cancer, Hepatic Carcinoma, Pulmonary Carcinoma, Pancreatic Carcinoma
- Trial name
- NCT07359586
- Where
- 2 sites in China
- Volunteers
- 1,200 people
- Sponsor
- Zhejiang University
Hepatocellular Carcinoma
Yliver as a Test to Early Diagnose HCC
Liver cancer (HCC) is the second cause of death related to cancer worldwide, with about 750,000 deaths from this cause in 2012. Although the early diagnosis of liver cancer increases the available treatment options, the methods…
- Trial name
- YliverDIAG (NCT03767764)
- Testing
- Test Yliver
- Where
- Spain
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- Corporacion Parc Tauli
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.